Publications


Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer.
Cancer Cell 2017 Apr 23;31(4):532-548.e7. Epub 2017 Mar 23.
Michigan Center for Translational Pathology, University of Michigan, 1400 East Medical Center Drive, 5316 CCGC, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan, 1400 East Medical Center Drive, 5316 CCGC, Ann Arbor, MI 48109, USA; Howard Hughes Medical Institute, University of Michigan, 1400 East Medical Center Drive, 5316 CCGC, Ann Arbor, MI 48109, USA; Department of Urology, University of Michigan, 1400 East Medical Center Drive, 5316 CCGC, Ann Arbor, MI 48109, USA; Comprehensive Cancer Center, University of Michigan, 1400 East Medical Center Drive, 5316 CCGC, Ann Arbor, MI 48109, USA. Electronic address:

BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer.
Mol Cancer Res 2016 Apr 20;14(4):324-31. Epub 2016 Jan 20.
Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan. Department of Pathology, University of Michigan, Ann Arbor, Michigan. Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan. Howard Hughes Medical Institute, University of Michigan, Ann Arbor, Michigan. Department of Urology, University of Michigan, Ann Arbor, Michigan.

Targeting the MLL complex in castration-resistant prostate cancer.
Nat Med 2015 Apr 30;21(4):344-52. Epub 2015 Mar 30.
1] Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan, USA. [2] Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA. [3] Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan, USA. [4] Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan, USA. [5] Howard Hughes Medical Institute, University of Michigan, Ann Arbor, Michigan, USA. [6] Department of Urology, University of Michigan, Ann Arbor, Michigan, USA.

Galanin modulates the neural niche to favour perineural invasion in head and neck cancer.
Nat Commun 2015 Apr 28;6:6885. Epub 2015 Apr 28.
1] Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry, Ann Arbor, Michigan 48109, USA [2] Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA [3] Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA.

BETs abet Tam-R in ER-positive breast cancer.
Cell Res 2014 Aug 8;24(8):899-900. Epub 2014 Jul 8.
1] Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA [2] Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA [3] Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA [4] Department of Urology, University of Michigan Medical School, Ann Arbor, MI 48109, USA [5] Howard Hughes Medical Institute, University of Michigan Medical School, Ann Arbor, MI 48109, USA.

The lncRNA PCAT29 inhibits oncogenic phenotypes in prostate cancer.
Mol Cancer Res 2014 Aug 16;12(8):1081-7. Epub 2014 Jul 16.
Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan. Department of Pathology, University of Michigan, Ann Arbor, Michigan. Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan. Howard Hughes Medical Institute, University of Michigan, Ann Arbor, Michigan.

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.
Nature 2014 Jun 23;510(7504):278-82. Epub 2014 Apr 23.
1] Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA [2] Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA [3] Howard Hughes Medical Institute, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA [4] Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA [5] Department of Urology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA.











Cetuximab attenuates metastasis and u-PAR expression in non-small cell lung cancer: u-PAR and E-cadherin are novel biomarkers of cetuximab sensitivity.
Cancer Res 2009 Mar 10;69(6):2461-70. Epub 2009 Mar 10.
Department of Experimental Surgery and Molecular Oncology of Solid Tumors, Medical Faculty Mannheim, University Heidelberg and DKFZ (German Cancer Research Center), Heidelberg, Germany.

Combination analysis of activator protein-1 family members, Sp1 and an activator protein-2alpha-related factor binding to different regions of the urokinase receptor gene in resected colorectal cancers.
Clin Cancer Res 2005 Dec;11(24 Pt 1):8538-48
Department of Experimental Surgery and Molecular Oncology, Universitaetsklinikum Mannheim and Department of Pediatrics, Dr. v. Haunersches Kinderspital, Munich, Germany.

BETting on a new prostate cancer treatment.
Cell Cycle 2014 6;13(13):2015-6. Epub 2014 Jun 6.
Michigan Center for Translational Pathology; University of Michigan Medical School; Ann Arbor, MI USA; Department of Pathology; University of Michigan Medical School; Ann Arbor, MI USA; Howard Hughes Medical Institute; University of Michigan Medical School; Ann Arbor, MI USA; Comprehensive Cancer Center; University of Michigan Medical School; Ann Arbor, MI USA; Department of Urology; University of Michigan Medical School; Ann Arbor, MI USA.


OF